Founded in 2015, Verge Genomics is an AI-driven biopharmaceutical drug discovery company that applies patient genomes, epigenomics, and gene expression for identifying novel effective drugs; stratify patient subpopulations, and therapeutic gene targets for accelerating clinical success. Verge Genomics is focusing on three neurodegenerative diseases: frontotemporal dementia (FTD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
Scope
The report provides information and insights into Verge Genomics, including:
- Overview of the company and its product offering
- Detailed insight into its business model, company type and headquarter
- Information on funding and partnership
- Biography of top management
Reasons to Buy
- Gain insights into Verge Genomics' business operations
- Gain insights into partnership and funding
- Gain understanding about its technology focus
Table of Contents
- Overview
- Technology Focus
- Product Overview
- Partnerships & Funding
- Key Employees
- Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Eli Lilly and Company
- Sheffield Institute for Translational Neuroscience (SITraN)
- Genomics England
- Datavant
